Trials / Completed
CompletedNCT04595786
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Growing evidence of Tranexamic Acid (TXA) being used to reduce blood loss and blood transfusions in various guidelines. However, the adverse effects of TXA especially seizure has always been a problem of concern, especially in neurosurgery. Therefore, this study aims to provide a scientific evidence for the safety of TXA in supratentorial meningiomas resection patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic acid | 20mg/kg TXA was prepared in a 50ml syringe for intravenous pump |
| DRUG | 0.9% saline | 0.9% saline was prepared in a 50ml syringe for intravenous pump |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2024-01-11
- Completion
- 2024-07-11
- First posted
- 2020-10-22
- Last updated
- 2025-03-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04595786. Inclusion in this directory is not an endorsement.